Entrada Therapeutics, Inc. (TRDA) Financial Ratios
7 years of historical data (2019–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: 12.45
30Y Low12.5·High12.5
P/FCF
N/A
—
5yr avg: 3.72
30Y Low3.7·High3.7
P/B Ratio
↓
0.92
↓-48% vs avg
5yr avg: 1.76
30Y Low1.4·High2.1
ROE
↑
-39.1%
↑-97% vs avg
5yr avg: -19.9%
30Y Low-40%·High20%
Debt/EBITDA
N/A
—
5yr avg: 1.17
30Y Low1.2·High1.2
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
TRDA Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Entrada Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $265M | $425M | $674M | $499M | $423M | $535M | — | — |
| Enterprise Value | $226M | $386M | $632M | $499M | $404M | $243M | — | — |
| P/E Ratio → | -1.97 | — | 10.29 | — | — | — | — | — |
| P/S Ratio | 10.43 | 16.73 | 3.20 | 3.87 | — | — | — | — |
| P/B Ratio | 0.92 | 1.39 | 1.57 | 2.06 | 1.99 | 1.79 | — | — |
| P/FCF | — | — | — | 3.72 | — | — | — | — |
| P/OCF | — | — | — | 3.57 | — | — | — | — |
P/E links to full P/E history page with 30-year chart
TRDA EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 15.18 | 3.00 | 3.87 | — | — | — | — |
| EV / EBITDA | — | — | 12.45 | — | — | — | — | — |
| EV / EBIT | — | — | 13.45 | — | — | — | — | — |
| EV / FCF | — | — | — | 3.72 | — | — | — | — |
TRDA Profitability
Margins and return-on-capital ratios measuring operating efficiency
Entrada Therapeutics, Inc. earns an operating margin of -613.7%. Operating margins have compressed from -2.5% to -613.7% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -39.1% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 83.9% | 83.9% | 100.0% | 100.0% | — | — | — | — |
| Operating Margin | -613.7% | -613.7% | 22.3% | -2.5% | — | — | — | — |
| Net Profit Margin | -565.5% | -565.5% | 31.1% | -5.2% | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -39.1% | -39.1% | 19.6% | -2.9% | -37.0% | -39.8% | — | — |
| ROA | -31.8% | -31.8% | 13.2% | -1.9% | -33.9% | -29.3% | -85.9% | -25.5% |
| ROIC | -35.8% | -35.8% | 11.2% | -1.1% | -72.6% | — | — | — |
| ROCE | -37.2% | -37.2% | 11.8% | -1.2% | -36.8% | -30.1% | -94.4% | -72.5% |
TRDA Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $90M exceeds total debt of $51M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.17 | 0.17 | 0.14 | 0.28 | 0.12 | — | — | — |
| Debt / EBITDA | — | — | 1.17 | — | — | — | — | — |
| Net Debt / Equity | — | -0.13 | -0.10 | 0.00 | -0.09 | -0.97 | — | — |
| Net Debt / EBITDA | — | — | -0.83 | — | — | — | — | — |
| Debt / FCF | — | — | — | 0.00 | — | — | — | — |
| Interest Coverage | — | — | — | — | -36.95 | — | — | — |
Net cash position: cash ($90M) exceeds total debt ($51M)
TRDA Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Entrada Therapeutics, Inc.'s current ratio of 12.53x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 2.33x to 12.53x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 12.53 | 12.53 | 11.15 | 2.33 | 9.55 | 44.46 | 11.89 | 9.08 |
| Quick Ratio | 12.53 | 12.53 | 11.15 | 2.33 | 9.55 | 44.46 | 11.89 | 9.08 |
| Cash Ratio | 12.09 | 12.09 | 10.64 | 2.22 | 8.59 | 43.32 | 11.62 | 8.77 |
| Asset Turnover | — | 0.07 | 0.40 | 0.27 | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | 6.37 | 16.63 | — | — | — | — |
TRDA Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Entrada Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | 9.7% | — | — | — | — | — |
| FCF Yield | — | — | — | 26.9% | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $41M | $39M | $33M | $31M | $31M | $31M | $1M |
Peer Comparison
Compare TRDA with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 TRDAYou | $265M | -2.0 | — | — | 83.9% | -613.7% | -39.1% | -35.8% | — |
 ARWR | $10B | -5957.4 | 84.4 | 64.9 | 97.1% | 11.9% | -0.5% | 9.3% | 3.0 |
 NTLA | $2B | -3.7 | — | — | 76.5% | -651.7% | -53.5% | -44.0% | — |
 BEAM | $3B | -39.9 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 EDIT | $304M | -1.7 | — | — | — | — | -198.1% | — | — |
 CRSP | $5B | -8.5 | — | — | -6537.0% | -16191.4% | -30.2% | -22.3% | — |
 SRPT | $2B | -2.8 | — | — | 59.9% | -29.9% | -53.5% | -31.4% | — |
 FOLD | $5B | -164.8 | 114.9 | 152.4 | 87.3% | 5.4% | -11.6% | 5.3% | 11.5 |
 RARE | $3B | -4.5 | — | — | 83.8% | -79.5% | -607.5% | -89.4% | — |
 AGEN | $135M | -1123.5 | — | — | 90.3% | -18.0% | — | — | — |
 IONS | $13B | -31.8 | — | — | 98.3% | -40.5% | -70.7% | -12.8% | — |
| Healthcare Median | — | 22.2 | 14.4 | 18.6 | 64.0% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 7 years · Updated daily
See TRDA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TRDA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare TRDA vs ARWR
Side-by-side business, growth, and profitability comparison vs Arrowhead Pharmaceuticals, Inc..
Start ComparisonTRDA — Frequently Asked Questions
Quick answers to the most common questions about buying TRDA stock.
What is Entrada Therapeutics, Inc.'s P/E ratio?
Entrada Therapeutics, Inc.'s current P/E ratio is -2.0x. The historical average is 10.3x.
What is Entrada Therapeutics, Inc.'s ROE?
Entrada Therapeutics, Inc.'s return on equity (ROE) is -39.1%. The historical average is -19.9%.
Is TRDA stock overvalued?
Based on historical data, Entrada Therapeutics, Inc. is trading at a P/E of -2.0x. Compare with industry peers and growth rates for a complete picture.
What are Entrada Therapeutics, Inc.'s profit margins?
Entrada Therapeutics, Inc. has 83.9% gross margin and -613.7% operating margin.